

IDEXX LABORATORIES INC /DE  
Form 4  
February 23, 2017

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
AYERS JONATHAN W

2. Issuer Name and Ticker or Trading Symbol  
IDEXX LABORATORIES INC /DE  
[IDXX]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)  
ONE IDEXX DRIVE  
(Street)

3. Date of Earliest Transaction (Month/Day/Year)  
02/22/2017

Director  10% Owner  
 Officer (give title below)  Other (specify below)  
Chairman, President & CEO

WESTBROOK, ME 04092

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/22/2017		M	V Amount (A) or (D) Price \$ 43.71	995,947	D	
Common Stock	02/22/2017		M	V Amount (A) or (D) Price \$ 38.795	1,045,947	D	
Common Stock	02/22/2017		S	V Amount (A) or (D) Price \$ 142.5484 (1)	1,014,152	D	
Common Stock	02/22/2017		S	V Amount (A) or (D) Price \$ 142.8419 (2)	1,010,947	D	
					98,000	I	

Common  
Stock

by Ayers  
Family  
Trust

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Security (Instr. 3 and 4)	8. Amount or Number of Shares
Incentive Stock Option (right-to-buy)	\$ 43.71	02/22/2017		M	2,286	<u>(3)</u> 02/13/2019	Common Stock	2,286
Non-Qualified Stock Option (right-to-buy)	\$ 38.795	02/22/2017		M	50,000	<u>(4)</u> 02/13/2018	Common Stock	50,000

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
AYERS JONATHAN W ONE IDEXX DRIVE WESTBROOK, ME 04092	X		Chairman, President & CEO	

## Signatures

/s/ Lily J. Lu, Attorney-in-Fact for Jonathan W. Ayers 02/23/2017

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

## Edgar Filing: IDEXX LABORATORIES INC /DE - Form 4

- Represents the weighted average sales price of the shares sold ranging from a low of \$141.80 to a high of \$142.795 per share. The
- (1) undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- Represents the weighted average sales price of the shares sold ranging from a low of \$142.80 to a high of \$143.00 per share. The
- (2) undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- Grant of option to buy 1,143 shares of IDEXX Laboratories, Inc. common stock that became exercisable on February 14, 2017, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The
- (3) number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
- Grant of option to buy 58,712 shares of IDEXX Laboratories, Inc. common stock that became exercisable in four annual installments of
- (4) 12,000 shares each beginning on February 14, 2012 and as to the remaining 10,712 shares on February 14, 2016, The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
- (5) Not applicable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.